GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cutia Therapeutics 2487.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.69

+2.24%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cutia Therapeutics

Its shares trade on HKEX under the ticker 2487.HK. It has been listed since 12 June 2023. In the fiscal year to 31 December 2025, it reported revenue of CN¥392.0m and a net loss of CN¥396.7m. At that date it held total assets of CN¥1.52bn and shareholders' equity of CN¥1.03bn.

Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
12 Jun 2023
Employees
175
Website
cutiatx.com ↗

Leadership

Pay as last reported

  • Dr. Lian Yong ChenNon-Executive Chairman of the Board, since 2019
  • Ms. Lele ZhangChief Executive Officer, Founder, Executive Director, since 2019
  • Mr. Yuqing HuangChief Financial Officer, Executive Director, since 2021
  • Dr. Lei LeiSenior Vice President - Research and Development Department
  • Mr. Jiaru WuSenior Vice President - Finance and Integrated Management Department
  • Ms. Jingxin XuSenior Vice President - Manufacturing and Quality Control Department
  • Ms. Chunna ZhangSenior Vice President - Regulatory Affairs Department
  • Mr. Qi ZhuChief Medical Officer
  • Ms. Sze Ting ChanCompany Secretary
  • Mr. Xiao HuangNon-Executive Director
  • Dr. Qin XieNon-Executive Director
  • Ms. Yunxia YangNon-Executive Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Shanghai with 175 employees
  • IPO completed on 2023-06-12
  • Focused on dermatology treatment solutions and clinical trials of CU-20401

Weaknesses

  • No specific financial data provided
  • Limited market presence mentioned
  • Dependent on a single product CU-20401

Opportunities

  • Expansion into domestic and overseas markets
  • Development of comprehensive dermatological solutions
  • Growing demand for dermatology treatments

Threats

  • No financial data available for risk assessment
  • Potential competition in dermatology market
  • Reliance on a single product for revenue growth

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.